Skip to main content

Advertisement

Table 2 Univariate and multivariate analyses for factors associated with overall survival of patients with intermediate to advanced HCC who received TACE with or without H101

From: Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study

Variable Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
PLT (vs. <100 × 109/L) 1.467 (0.993–2.166) 0.054   NI
ALT (vs. <40 U/L) 1.267 (0.993–1.617) 0.057   NI
AST (vs. <45 U/L) 2.037 (1.568–2.646) <0.001 0.228
ALB (vs. <35 g/L) 0.704 (0.512–0.968) 0.031 0.424
TBIL (vs. <20 mmol/L) 1.213 (0.915–1.610) 0.180   NI
IBIL (vs. <15 mmol/L) 1.195 (0.809–1.765) 0.372   NI
ALP (vs. <100 U/L) 2.432 (1.859–3.180) <0.001 1.494 (1.116–2.001) 0.007
CRP (vs. <8.2 mg/L) 2.180 (1.722–2.759) <0.001 0.102
AFP (vs. <25 ng/mL) 1.547 (1.200–1.994) 0.001 1.389 (1.064–1.814) 0.016
HBsAg (vs. negative) 0.658 (0.413–1.048) 0.078   NI
HBV-DNA (vs. <100 IU/mL) 1.104 (0.876–1.392) 0.403   NI
NLR (vs. <3) 1.477 (1.145–1.904) 0.003 0.08
Tumor size (vs. <5 cm) 4.523 (3.156–6.481) <0.001 3.120 (2.115–4.602) <0.001
Tumor number (vs. single) 1.303 (1.019–1.668) 0.035 0.409
Splenomegaly (vs. no) 1.179 (0.928–1.499) 0.178   NI
Metastasis (vs. no) 3.668 (2.377–5.662) <0.001 2.111 (1.342–3.321) 0.001
Vascular invasion (vs. no) 1.835 (1.443–2.335) <0.001 1.292 (1.001–1.666) 0.049
Antiviral therapy (vs. no) 0.752 (0.596–0.950) 0.017 0.118
TACE (vs. without H101) 0.711 (0.563–0.896) 0.004 0.623 (0.492–0.789) <0.001
  1. HR hazard ratio, CI confidence interval, NI not included. Other abbreviations as in Table 1
  2. – Data not shown due to no significance